Cargando…

Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis

To perform a systematic review and network meta-analysis to compare the survival benefit and safety profile of current available second-line treatment options of metastatic renal cell carcinomav. METHODS: PubMed, EMBASE, Web of Science, and Cochrane Library were systematically researched for eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Yang, Hou, Haifeng, Han, Zhenhua, Liu, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478350/ https://www.ncbi.nlm.nih.gov/pubmed/36123840 http://dx.doi.org/10.1097/MD.0000000000030333

Ejemplares similares

Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020)

Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Goudarzi, Zahra, et al.
Publicado: (2023)

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
por: Mitsogiannis, Iraklis C., et al.
Publicado: (2022)

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
por: Bosma, Nicholas A., et al.
Publicado: (2022)

Metastatic clear cell renal carcinoma – an unusual response to Temsirolimus in second line therapy
por: Stanculeanu, DL, et al.
Publicado: (2016)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers
por: Parosanu, Andreea Ioana, et al.
Publicado: (2023)

Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
por: Heng, Daniel Y., et al.
Publicado: (2014)

Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
por: Chrom, Pawel, et al.
Publicado: (2018)

Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis
por: Eggers, Hendrik, et al.
Publicado: (2017)

Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma
por: Tremblay, Gabriel, et al.
Publicado: (2019)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Clinical and Pathological Characteristics of Metastatic Renal Cell Carcinoma Patients Needing a Second-Line Therapy: A Systematic Review
por: Longo, Nicola, et al.
Publicado: (2020)

Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2023)

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
por: Elaidi, Reza, et al.
Publicado: (2020)

The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis
por: Zhan, Ze-Jiang, et al.
Publicado: (2021)

Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment
por: Kok, Victor C., et al.
Publicado: (2016)

Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis
por: Wang, Junpeng, et al.
Publicado: (2019)

Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience
por: Pehlivan, Metin, et al.
Publicado: (2023)

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
por: Lakomy, Radek, et al.
Publicado: (2017)

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
por: Gamulin, Marija, et al.
Publicado: (2020)

Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
por: Solimando, Antonio Giovanni, et al.
Publicado: (2021)

Second-Line Systemic Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
por: Yoon, Hyun Sik, et al.
Publicado: (2019)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis
por: Karner, Charlotta, et al.
Publicado: (2019)

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
por: Martín-Aguilar, Ana Elena, et al.
Publicado: (2021)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis
por: He, Yan, et al.
Publicado: (2022)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines
por: Gil, Lucia, et al.
Publicado: (2022)

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
por: Qin, Shukui, et al.
Publicado: (2015)

Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
por: Arnold, D, et al.
Publicado: (2018)

Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma
por: Lin, Dengqiang, et al.
Publicado: (2023)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis
por: Qin, Suyang, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
por: Lauren, Brianna, et al.
Publicado: (2020)

The Complete Response of a Renal Cell Carcinoma Metastatic to Brain, Lungs, and Liver to Second-Line Nivolumab: A Case Report
por: Haghpanah, Mahsa, et al.
Publicado: (2022)

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
por: Gan, Chun Loo, et al.
Publicado: (2021)

Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2019)

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
por: Manz, Kirsi M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qu05h011a8vjploflfrnlp59gq